{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-049197","form_type":"8-K","ticker":"SNSE","cik":"0001829802","company_name":"Sensei Biotherapeutics, Inc.","filed_at":"2024-02-28T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.802450+00:00","generated_at":"2026-06-05T09:24:22.502214+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Sensei Biotherapeutics FY 2023 net loss $34.1M; cash into Q4 2025; SNS-101 data due Q2 2024","bullets":["Net loss $34.1M in FY2023 vs $48.6M in FY2022; R&D expense fell to $18.3M from $30.4M.","Cash, equivalents, and marketable securities $65.8M at Dec 31, 2023 (down from $107.1M); runway now into Q4 2025.","SNS-101 Phase 1/2: topline efficacy/biomarker data expected Q2 2024 (ahead of prior guidance); no DLTs in 33 patients.","Resource realignment: paused preclinical TMAb programs (SNS-102, SNS-103, SNS-201) to focus on SNS-101.","Appointed Ron Weitzman as part-time CMO (Jan 2024) and Stephanie Krebs as CBO (Nov 2023)."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-049197","json":"https://secwatch.observer/filing/0001193125-24-049197.json","markdown":"https://secwatch.observer/filing/0001193125-24-049197.md","text":"https://secwatch.observer/filing/0001193125-24-049197.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1829802/000119312524049197/0001193125-24-049197-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1829802/000119312524049197/d770175d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-05T09:24:22.502214+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"36c4912089cc12947983c837cc0120f2bbfb7942","claim":"Sensei Biotherapeutics, Inc. reported financial results for full year ended December 31, 2023.","evidence_excerpt":"On February 28, 2024, Sensei Biotherapeutics, Inc. issued a press release announcing its financial results for the full year ended December 31, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1829802/000119312524049197/0001193125-24-049197-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"full year ended December 31, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}